Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities

Value in Health

Volumn 10, Issue 5, 2007, Pages 377-385

  Schachter, Asher D ^a,b,c   Ramoni, Marco F ^b,c,d   Baio, Gianluca ^e,f   Roberts Jr , Thomas G ^g   Finkelstein, Stanley N ^h  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LABORATORY FOR MOLECULAR MEDICINE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Fondazione CERM   (Italy)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bayesian network; Monte Carlo simulation; New chemical entity; Pharmacoeconomics; Prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; BAYES THEOREM; DRUG COST; DRUG INDUSTRY; FALSE NEGATIVE RESULT; FINANCIAL MANAGEMENT; MATHEMATICAL MODEL; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY SAMPLE; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 34748871359     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00191.x     Document Type: Article

References (30)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 22 : 151 85.
2. PublicCitizen. Rx R&D Myths: The Case Against the Drug Industry's R&D 'Scare Card'. Congress Watch 2001.
3. Relman AS, Angell M. America's other drug problem. how the drug industry distorts medicine and politics. New Repub 2002 227 : 27 41.
4. Rawlins MD. Cutting the cost of drug development? Nat Rev Drug Discov 2004 3 : 360 4.
5. Riggs TL. Research and development costs for drugs. Lancet 2004 363 : 184.
6. Scherer FM. The pharmaceutical industry - prices and progress. N Engl J Med 2004 351 : 927 32.
7. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995 58 : 1 14.
8. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991 10 : 107 42.
9. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001 69 : 297 307.
10. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002 20 (Suppl. 3 S1 10.
11. Schachter AD. Probabilistic Modeling of the Drug Development Domain: A Bayesian Domain-Knowledge Application for Pharmacovigilance [Masters of Science]. Cambridge, MA : Massachusetts Institute of Technology, 2003.
12. Schachter AD, Ramoni MF Inventors. Method and apparatus for evaluating new chemical entities. USPTO patent application # 20050021237, USA, 2005.
13. Roberts TG Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004 292 : 2130 40.
14. Pearl J. Fusion, propagation, and structuring in belief networks. Artif Intell 1986 29 : 241 88.
15. Pearl J. Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. San Mateo, CA : Morgan Kaufmann, 1988.
16. Winston PH, Narasimhan S. On to Java (3rd ed.). Boston, MA : Addison-Wesley, 2001.
17. Dreiseitl S, Ohno-Machado L, Binder M. Comparing three-class diagnostic tests by three-way ROC analysis. Med Decis Making 2000 20 : 323 31.
18. Bureau of Economic Analysis. National Economic Accounts. In : USDOC, ed. Available from: http://www.bea.gov/bea/dn/home/gdp.htm [Accessed July 12, 2005].
19. Grabowski HG, Vernon J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 2000 18 (Suppl. 1 S21 32.
20. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2005. Accessed from: http://www.r-project.org [Accessed June 17, 2005].
21. Frantz S, Smith A. New drug approvals for 2002. Nat Rev Drug Discov 2003 2 : 95 6.
22. Sheck L, Cox C, Davis HT, et al. Success rates in the United States drug development system. Clin Pharmacol Ther 1984 36 : 574 83.
23. Bienz-Tadmor B, Dicerbo PA, Tadmor G, Lasagna L. Biopharmaceuticals and conventional drugs: clinical success rates. Biotechnology (N Y) 1992 10 : 521 5.
24. Struck MM. Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future. Biotechnology (N Y) 1994 12 : 674 7.
25. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics 1995 7 : 152 69.
26. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med 1985 4 : 521 6.
27. Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics 1988 44 : 219 27.
28. Berry DA. A case for Bayesianism in clinical trials. Stat Med 1993 12 : 1377 93 Discussion 1395-404.
29. Spiegelhalter DJ, Freedman LS, Parmar MKB. Applying Bayesian ideas in drug development and clinical trials. Stat Med 1993 12 : 1501 11.
30. De Ridder F. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol 2005 96 : 235 41.